Liraglutide and Cardio-Metabolic Risk Markers

University of Palermo

Status: Completed

Conditions: Type-2 Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT01715428

LIRAGLUTIDE UNIPA

Details and patient eligibility

About

Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.

Full description

In details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.

Enrollment: 300 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with a diagnosis of type-2 diabetes

Exclusion criteria

• severe hepatic or renal diseases

Trial design

300 participants in 1 patient group

Liraglutide

Description:

administration of liraglutide at 1.2 mg/daily